M&A
J&J to Acquire Ollin
Johnson & Johnson announced the acquisition of Ollin Biosciences for $2.2 billion upfront and up to $1.125 billion in milestones, obtaining OLN324 and OLN102. Blackstone will provide $750 million to support OLN324 phase 3 development in exchange for a single-digit sales participation and regulatory and sales milestones. Two global phase 3 trials of OLN324 in wet age-related macular degeneration began in September 2026; a diabetic macular edema phase 3 trial is also planned.
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.